Recent studies in mice and humans have emphasized an important contribution of host-reactive minor histocompatibility antigen (mH)-specific lymphokine-secreting donor T-helper cells (Th) for the induction of acute graft-versushost disease (GVHD) after allogeneic bone marrow transplantation (BMT). By using limiting dilution (LD) and clonal specificity analyses, we investigated in 14 patients with and without acute GVHD after non-T-depleted HLA-identical sibling BMT whether posttransplant host-reactive mHspecific interleukin-2 (IL-2)-secreting Th are involved in the development of clinically significant acute GVHD and the establishment of tolerance. At different time intervals posttransplant (I, days 0 through 45; II, days 45 through 90; 111, days 90 through 180). host-specific IL-2-secreting Th-precursors (Th-p) were quantitatively assessed in six patients during clinically apparent grade 11-111 acute GVHD. Frequencies of responding Th-p ranged from 1 /13,000 to ESPITE IMPROVEMENTS in posttransplant immu-
Recent studies in mice and humans have emphasized an important contribution of host-reactive minor histocompatibility antigen (mH)-specific lymphokine-secreting donor T-helper cells (Th) for the induction of acute graft-versushost disease (GVHD) after allogeneic bone marrow transplantation (BMT). By using limiting dilution (LD) and clonal specificity analyses, we investigated in 14 patients with and without acute GVHD after non-T-depleted HLA-identical sibling BMT whether posttransplant host-reactive mHspecific interleukin-2 (IL-2)-secreting Th are involved in the development of clinically significant acute GVHD and the establishment of tolerance. At different time intervals posttransplant (I, days 0 through 45; II, days 45 through 90; 111, days 90 through 180). host-specific IL-2-secreting Th-precursors (Th-p) were quantitatively assessed in six patients during clinically apparent grade 11-111 acute GVHD. Frequencies of responding Th-p ranged from 1 /13,000 to ESPITE IMPROVEMENTS in posttransplant immu-D nosuppressive therapy, grade 11-IV acute graft-versushost disease (GVHD), mediated by host-reactive donor T cells present in the bone marrow (BM) inoculum, still remains a major cause of morbidity and mortality after non-T-depleted allogeneic HLA-identical sibling BM transplantation (BMT).'.' Between genotypically HLA-identical sibling donor-patient pairs, host-reactive donor T cells are, by definition, directed against minor histocompatibility (mH) antigens, presented in the context of molecules encoded by the major histocompatibility complex (MHC). 3, 4 From murine models, an important contribution of hostreactive mH-specific donor T-helper cells (Th) to the induction of acute GVHD has been ~uggested.~-~ Recent evidence in humans has indicated that host-reactive donor Th, defined as noncytolytic proliferating T cells, correlate with the incidence of severe acute GVHD after genotypically HLAidentical sibling BMT. "1' ' Apart from the well-established cooperation with cytotoxic T-lymphocyte precursors (CTL-P),'~.'~ host-reactive Th may induce tissue damage in acute GVHD by the release of various intermediary lymphokines, such as interleukin-2 (IL-2),I5,I6 tumor necrosis factor-a (TNF-CX),'~-*~ and interferon-y (IFN).*' More recently, we have shown that high and low frequencies of pretransplant host-reactive mH-specific IL-2-secreting donor Th-precursors (Th-p) correlate well with the posttransplant development of grade 11-111 and grade 0-1 acute GVHD, respectively.** To confirm these results in the posttransplant setting and to analyze whether host-reactive Th are involved in the induction of acute GVHD and the establishment of tolerance, we examined the frequencies of hostspecific Th-p in patients with and without acute GVHD after genotypically HLA-identical sibling marrow grafting. The results clearly indicate that the development of acute GVHD is critically dependent on the presence of posttransplant hostreactive IL-2-secreting Th.
1 /I 74,000. The presence of host-specific Th-p was significantly correlated with the development of grade 11-111 acute GVHD (P = .0003 by Fisher's exact test). The detectability of host-specific Th-p preceded the clinical onset of grade 11-111 acute GVHD. Host-specific Th-p were no longer detectable after the clinical resolution of grade 11-111 acute GVHD. No subsequent chronic GVHD was observed in these patients. However, prolonged occurrence of hostspecific Th-p was accompanied by clinically persisting acute GVHD and the onset of secondary chronic GVHD. In patients with no acute GVHD (grade 0) (n = 7) and grade I (n = 1) acute GVHD, host-specific Th-p were not detectable at all. We conclude that host-reactive Th are critically involved in the development and maintenance of acute GVHD and may contribute to the establishment of tolerance after genotypically HLA-identical sibling BMT. 0 1993 by The American Society of Hematology.
MATERIALS AND METHODS
Patients. Fourteen mixed lymphocyte culture (MLC)-negative and lymphocyte crossmatch-negative, genotypically HLA-identical sibling donor-patient pairs were investigated posttransplant for the presence of circulating host-specific Th-p. The relevant clinical details of the study group are listed in Table 1 . All patients received non-T-depleted marrow grafts from their genotypically HLA-identical sibling donors in the BMT-Unit of the Ulm University Hospital (Ulm, Germany). Successful engraftment was achieved in all patients. This was proved by assessment of erythrocyte antigens of donor-type after BMT, by posttransplant detection of donor sex chromosomes in the case of sex mismatch between donor and recipient, and by the amplification of variable number of tandem repeats (VNTR) in cell sorter-separated T-lymphocyte and monocyte cell populations using the polymerase chain reaction (PCR).23 Even in three cases of early leukemic relapse (patients no. 11, 12, and 14), T lymphopoiesis appeared to be of complete donor origin, as determined by the latter approach (data not shown). in all patients, cyclosporine (CsA) and methotrexate (Mtx) were administered as posttransplant immunosuppressive agents for the prevention of GVHD, as previously reported.' The diagnosis of acute and chronic GVHD was established by clinical and histopathologic criteria.24 Chronic GVHD was classified according to Sullivan et aLZ5 Six patients developed grade II-111 acute GVHD. Grade I acute GVHD was diagnosed in one patient. Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; SAA, severe aplastic anemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CR. complete remission; CP. chronic phase; AP, accelerated phase; TBI, fractionated total body irradiation; TLI, total lymphoid irradiation; Ctx, endoxan; Dnr, daunorubicine; Bus, busulfan; VP-16, Etoposide; S, Skin; NA, not applicable.
NIERLE ET AL
Seven patients never showed any clinical signs of acute GVHD. Two patients developed secondary chronic GVHD and one patient developed primary chronic GVHD. GVHD was treated with high-dose prednisolone, started at a dosage of 10 to 20 mg/kg, reduced to 1 to 2 mg/kg in responding patients for 7 to 10 days, and continued at 0.5 mg/kg until resolution of the symptoms.
The culture medium used was RPMI-1640
, 100 j&mL streptomycin, and 100 U/mL penicillin. The culture medium used for restimulation was supplemented with 200 Wg/mL netilmycin. 
In vitro Epstein-Barr virus-transformed B-lymphoblastoid cell lines (EBV-LCL). For the establishment of pretransplant donor
and host as well as completely HLA-mismatched unrelated EBV-LCL, E-rosette-purified T and non-T cells were prepared from PBMC by incubation with neuraminidase-treated sheep red blood cells (SRBC), as previously described.26 Non-T cells ( 5 X 106/mL) were infected for 4 hours at 37°C with mycoplasma-free supematant (SN) of the EBV-producing B95.6 cell line. After washing, EBVinfected cells were maintained in RPMI-1640 medium supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS; Biochrom). Continuously growing EBV-LCL were found free of mycoplasma contamination on repeated testing and served as restimulator cells.
Irradiation. Stimulator and restimulator cells were irradiated with 2,000 rad and 4,000 rad, respectively, from a "' Cs source (NuclearData, Frankfurt, Germany).
HLA-typing of PBMC as well as HLA-retyping of EBV-LCL from pretransplant sibling donor-pa-
HLA serotyping and genotyping.
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843 tient pairs and unrelated healthy volunteers were performed by conventional serotyping of HLA-A, -B, -C, -DR, and -DQ alleles and by oligonucleotide typing of HLA-DPB 1 allele^.^' All sibling donor-patient pairs were negative in the standard MLC and the lymphocyte crossmatch, and were genotypically matched for HLA-A, -B, -C, -DR, -DQ, and -DPBI alleles (data not shown).
The methodologic details of LD analysis of human Th-p have been recently
In brief, replicate microcultures (n = 16) were set up in 96-well V-shaped microtiter plates (Nunc, Wiesbaden, Germany) with graded numbers of posttransplant patient PBMC responder cells in the presence of 1 X IO4 irradiated stimulator cells and I O U human recombinant IL-2 (rIL-2)/mL (Eurocetus, Amsterdam, The Netherlands) in a final volume of 200 pL/well. Pretransplant host PBMC, pretransplant donor PBMC, or completely HLA-mismatched unrelated PBMC served as irradiated stimulator cells. LD cultures for posttransplant frequency analysis of host-reactive, donor-reactive (autoreactive), and allo-MHC-reactive Th-p were set up simultaneously for a given patient. A culture period of 14 days has been proved optimal for frequency calculation of mH-specific Th-p (data not shown). Thus, restimulation of LD cultures was performed after 14 days. Cultures were washed twice with PBS and split into two aliquots, the first of which was restimulated with the original primary antigen and the second of which received pretransplant cells from the donor (if originally primed to host) or pretransplant host cells (donor and HLA-mismatched primed cultures) ( I X lo5 irradiated EBV-LCL restimulator cells/ well). After 20 to 24 hours, 75 pL of SN was removed and transferred to flat-bottom microtiter plates (Nunc) for IL-2 analysis.
For clonal specificity analysis of posttransplant anti-host-induced Th-p from LD cultures, individual IL-2-producing colonies were only evaluated if they displayed a chance for clonality of greater than 70'70, as calculated from the respective frequency values.
IL-2 activity was determined using a colorimetric bioassay, as recently Briefly, this approach 
RESULTS
Frequency and specificity of posttransplant host-reactive Th-p. Fourteen patients with grade 11-111 (n = 6) and grade 0-1 (n = 8) acute GVHD (Table 1) were investigated for the presence of circulating host-specific Th-p at different time intervals posttransplant. All patients received non-T-depleted marrow grafts from their MLC-negative and lymphocyte crossmatch-negative, genotypically HLA-identical sibling donors. As shown in Table 2 , posttransplant host-reactive Th-p were detectable in six patients with grade 11-111 acute GVHD. Frequencies of responding Th-p ranged from I / 13,000 to 1/174,000. The presence of posttransplant hostreactive Th-p was highly correlated with the development of grade 11-111 acute GVHD, as determined by Fisher's exact test ( P = .0003). Host-reactive Th-p occurred as early as 20 days posttransplant and preceded the clinical onset of grade 11-111 acute GVHD (patients no. 9, 10, and 13). After resolution of the clinical symptoms of grade 11-111 acute GVHD, host-reactive Th-p were no longer observed (patients no. 5, 8, and 9). These patients did not develop subsequent chronic GVHD. However, prolonged detectability of host-reactive Th-p was associated with clinically persisting acute GVHD and onset of secondary chronic GVHD (patients no. 10 and 13). In contrast, among eight patients with no (grade 0) (n = 7) or grade I (n = 1) acute GVHD, host-reactive Th-p have not been found at all (Fig 1A through C) . Although one of these patients (patient no. 7) developed primary chronic GVHD at day 108, we did not detect host-reactive Th-p at this time (Fig IC) . The antigen specificity of host-reactive Th-p in patients with grade 11-111 acute GVHD was indicated by the finding that frequencies of anti-host-induced Th-p were beyond the threshold of detectability (<I /400,000) after restimulation of split-well cultures with pretransplant donor cells (Fig 1A through C) . No autologous background reactivity occurred after primary induction of posttransplant Th-p with pretransplant donor stimulator cells (Fig IA through C) . In all 14 patients, frequencies of posttransplant allo-MHC-specific Th-p were individually and on average higher in magnitude as compared with hostreactive Th-p (Fig 1A through C) , but were below those obtained in pretransplant donor and unrelated normal control individuals (data not shown). However, frequencies of allo-MHC-reactive Th-p were not influenced by acute or chronic GVHD, application of steroids, and infectious complications.
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Clonal specificity of posttransplant anti-host-induced Th-p. After restimulation of anti-host-induced posttransplant Th-p with pretransplant donor cells, a small proportion of Th colonies produced IL-2. However, frequencies of antihost-induced donor-reactive Th-p could not be determined because the few colonies showing this reactivity were both detectable independent of the responder cell dose seeded and not sufficient for frequency calculation. Therefore, the antigen specificity of anti-host-induced Th-p among patients with grade 11-111 acute GVHD was quantitatively confirmed at the clonal level. The relative distribution of cumulative posttransplant host-specific IL-2-producing Th colonies was evaluated from LD split-well cultures, displaying a chance of clonality of greater than 7070, as estimated from the respective frequency values. This selection was performed not only to sustain a high enough chance for clonality but also 
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to obtain a sufficient number of IL-2-producing colonies for specificity analysis. Results are summarized in Table 3 . After restimulation of split-well cultures with pretransplant host primary stimulating antigens and pretransplant donor antigens among patients with grade 11-111 acute GVHD, the vast majority (63% to 83%) of posttransplant anti-host-induced IL-2-producing Th colonies appeared to be exclusively specific for host antigens. Because only few colonies of antihost-induced donor-reactive Th-p were found among cultures with even higher responder cell numbers, a similar high proportion of host-specific IL-2-producing colonies was detectable among cultures with a less than 70% chance for clonality (data not shown).
DISCUSSION
Our study demonstrates a significant correlation between the detection of posttransplant host-specific Th-p and the presence of grade 11-111 acute GVHD in HLA-identical sibling BMT. The persistence of host-specific Th-p was associated with the development of secondary chronic GVHD. The in vitro detectability of posttransplant host-specific Th-p preceded the clinical onset of grade 11-111 acute GVHD, as recently demonstrated for host-reactive CTL-P.~' Other factors, such as patient age, sex mismatch, and previous donor pregnancy, correlated with neither the Th functional status posttransplant nor with the development of acute GVHD.
Between genotypically HLA-identical sibling donor-host pairs, host-reactive donor T cells are, by definition, directed against mH antigens, presented in the context of molecules encoded by the MHC3x4 Recently, we have demonstrated that between genotypically HLA-identical sibling individuals, mH-specific naive Th-p as well as previously in vivo-primed memory Th-p are detectable in substantial frequencies within the class I MHC-restricted CD8+ and the class I1 MHC-restricted CD4' T-cell subsets.31 The relative contribution of murine CD8' and CD4' T cells to GVHD directed against mH antigens vanes according to the particular strain combination e~a m i n e d .~'~ In humans, it has been suggested that Th, defined as noncytolytic proliferating T cells, are involved in posttransplant anti-host mH-specific T-cell responses.334 An important role for mH-reactive Th in the induction of acute GVHD after HLA-identical sibling BMT has been further indicated by the recent finding that the posttransplant detectability of host-specific noncytolytic proliferating T cells rather than CTL correlates with the incidence of severe acute GVHD.'0311 More recently, we have demonstrated that high frequencies of pretransplant host-reactive mH-specific donor Th-p significantly correlate with the development of grade 11-111 acute GVHD in HLA-identical sibling BMT." Accordingly, in four of six patients with grade 11-111 acute GVHD and detectable host-specific Th-p posttransplant (patients no. 5, 9, 13, and 14), high frequencies of host-specific donor Thp have been determined pretransplant.22 Among six of eight patients with grade 0-1 acute GVHD and undetectable hostreactive Th-p posttransplant (patients no. 1, 3, 4, 7, 1 1, and I2), only low frequencies of anti-host-induced donor Th-p, which had to be attributed to an autologous background response, were observed pretransplant. 22 The remaining four patients of the present study (patients no. 2, 6, 8, and 10) have not yet been analyzed pretransplant, By which mechanisms do host-reactive mH-specific donor Th contribute to the induction of acute GVHD? According to the classical concept of T-T cell cooperation, mH-specific Th are essential for the IL-2-mediated proliferation and differentiation of activated mH-specific CTL-p. I2-I4 Host-reactive mH-specific CTL have been observed during GVHD3z4 and histologic GVHD lesions may result from direct CTLmediated target cell lysis.32 However, anti-host-directed mHspecific CTL can be generally isolated posttransplant, regardless of whether GVHD occurs.10 As a consequence, the induction of acute GVHD may depend on the posttransplant presence of host-reactive Th, capable of providing help via IL-2 release for the proliferation and differentiation of hostreactive CTL-p, which may trigger acute GVHD after maturation into cytolytic effector T cells. Apart from the cooperation with CTL-p, Th per se are capable of directly inducing a lethal GVHD-like syndrome via IL-2.I6 Histologic lesions in acute GVHD may also result from IL-2.15 Recent experimental data emphasize the central role of various other cytokines such as TNF-a,17-20 IFN," and IL-133.34 in the induction of acute GVHD. Inhibition of TNF-a and IL-1 by anti-TNF-a antibody2' and IL-1 receptor antagonist,34 respectively, prevents GVHD in animal models to some extent. TNF-a and IFN are produced by IL-2-secreting Th.35-37 More distal from Th, IFN may activate monocytes to release TNF and IL-1 and thereby further augment the lymphokinedriven inflammatory process underlying acute GVHD. Both IFN and TNF-a increase the expression of class I and class I1 MHC molecules as well as bound mH peptides on GVHD target tissue^^*,^^ and thus participate in T-cell-dependent 
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events during acute GVHD. In view of these various Thdependent mechanisms and the results reported in the present study, Th may be involved as critical key effector cells in the pathophysiologic process underlying the development of acute GVHD.
In one patient with grade I acute GVHD, in six patients with no (grade 0) acute GVHD, and in one patient with primary chronic GVHD, posttransplant host-specific Th-p were not detectable at all. The same became evident after resolution of the clinical symptoms of grade 11-111 acute GVHD in three patients who did not develop subsequent chronic GVHD. The lack of host-specific Th-p in these patients was neither due to an overall absence of posttransplant Th-p nor to an effector cell compartimentalization as a result of steroid application. Thus, the pool size of circulating allo-MHC-reactive Th-p, although decreased to some extent posttransplant, as already established,40 remained unaffected by steroid therapy, the presence or absence of GVHD, and infectious complications. We conclude that the lack of posttransplant host-reactive Th-p is associated with the absence of severe GVHD, because intermediary cytokines would not be produced and host-reactive C T L p would not be able to undergo IL-2-driven proliferation and differentiation to function as cytolytic effector T cells on GVHD target tissues. Whether m H compatibility between sibling donor-host pairs may lead to nonresponsiveness at the level of Th-p still remains unclear.
In patients with primary detection of host-specific Th-p during clinically apparent grade 11-Ill acute GVHD and subsequent disappearance of these cells accompanied by the clinical resolution of acute GVHD without onset of chronic GVHD, secondary Th nonresponsiveness cannot be due to m H compatibility between donor and recipient. Does secondary nonresponsiveness of host-reactive mH-specific Thp represent the establishment of tolerance at the level of IL-2-producing T lymphocytes? Tolerance is observed in a large proportion of mH-mismatched marrow graft recipient^.^'.^^ The mechanisms responsible for the establishment of tolerance after genotypically HLA-identical sibling BMT are complex and not completely defined. It is well established that CsA acts to inhibit the synthesis of various lymphokines such as IL-1, 1L-2, TNF-a, and IFN.37,43,44 Apart from the immunosuppressive therapy including steroid application, various complex mechanisms of central thymic and peripheral postthymic tolerance induction may contribute to tolerance after BMT. Central tolerance induced by clonal thymic deletion of potentially host-reactive immature T ~e l l s~~,~~ is unlikely to be involved in the patients reported here, as mature postthymic donor T cells were grafted with the non-T-depleted marrow inoculum. Whether different nonexclusive mechanisms of peripheral tolerance, including clonal deletion of mature postthymic T cells by the veto p h e n~m e n o n~' -~~ and induction of clonal anergy of mature postthymic T cells by inadequate or absent costimulatory signal^,^^-^* may contribute to tolerance at the level of posttransplant host-reactive Th-p is an open question at present.
In conclusion, our data support the view that host-reactive Th are critically involved in the development and maintenance of acute GVHD. IL-2-secreting Th may also serve as target cells for yet poorly defined mechanisms of peripheral tolerance. These results may further our understanding of acute GVHD and tolerance induction after allogeneic HLAidentical sibling BMT.
